Magnetic resonance molecular imaging of the HER-2/neu receptor.

The HER-2/neu receptor is a member of the epidermal growth factor family and is amplified in multiple cancers. It is under intense investigation both as a prognostic marker and for therapy, using monoclonal antibodies targeted against the receptor. We have developed a novel two-component gadolinium-based MR contrast agent to image the HER-2/neu receptor. Positive T1 contrast in MR images was generated by the specific binding of avidin-gadolinium complexes to tumor cells prelabeled with a biotinylated anti-HER-2/neu antibody. Significant intensity enhancement was observed in HER-2/neu-expressing cell lines and in vivo in a breast cancer model. Potential applications of this approach may include determination of the HER-2/neu status for prognosis and for selecting tumors for monoclonal antibody therapy.

[1]  F. Virzi,et al.  Investigations of avidin and biotin for imaging applications. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  M. Ferrari,et al.  Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients , 1999, European Journal of Nuclear Medicine.

[3]  M. Brechbiel,et al.  Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores , 2001, Magnetic resonance in medicine.

[4]  J A Frank,et al.  Neurotransplantation of magnetically labeled oligodendrocyte progenitors: magnetic resonance tracking of cell migration and myelination. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  G. Hortobagyi.  Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. , 2001, Seminars in oncology.

[6]  M. Brechbiel,et al.  3D‐micro‐MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties , 2001, Magnetic resonance in medicine.

[7]  E. Jaffee,et al.  HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. , 2000, Cancer research.

[8]  A. Reid,et al.  Gadolinium Chloride Toxicity in the Rat , 1997, Toxicologic pathology.

[9]  A. Sahin,et al.  HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[11]  R Weissleder,et al.  Magnetically labeled cells can be detected by MR imaging , 1997, Journal of magnetic resonance imaging : JMRI.

[12]  P. Caliceti,et al.  Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. , 2001, Cancer biotherapy & radiopharmaceuticals.

[13]  M. Wilchek,et al.  Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. , 1990, European journal of biochemistry.

[14]  E. Harpur,et al.  Gadolinium chloride toxicity in the mouse , 1998, Human & experimental toxicology.

[15]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. D. De Braud,et al.  Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin , 1999, European Journal of Nuclear Medicine.

[17]  W. Ebert,et al.  The Demonstration of Human Tumors on Nude Mice Using Gadolinium‐Labelled Monoclonal Antibodies for Magnetic Resonance Imaging , 1993, Investigative radiology.

[18]  G. Hortobagyi,et al.  Targeting HER2: recent developments and future directions for breast cancer patients. , 2001, Seminars in oncology.

[19]  Donald S. Williams,et al.  Detection of single mammalian cells by high-resolution magnetic resonance imaging. , 1999, Biophysical journal.

[20]  David A. Cheresh,et al.  Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.

[21]  R Weissleder,et al.  Measuring transferrin receptor gene expression by NMR imaging. , 1998, Biochimica et biophysica acta.

[22]  M. Luyckx,et al.  Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability. , 1996, Methods and findings in experimental and clinical pharmacology.

[23]  D Artemov,et al.  Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. , 2001, Neoplasia.